In addition, resistant leukemias that emerged during in vivo treatment with MEK and PI3K inhibitors invariably retained multiple retroviral integrations found in the corresponding drug-sensitive parental T-ALL, but frequently showed loss of Notch1 mutation [20]. This evidence concerns the gene MAP2K7 and leukemia.